Colossal tackles devil facial tumour disease with oral vaccine
The Colossal Foundation partners with University of Tasmania to develop a field-ready vaccine and explore genetic resistance using a dunnart colony.
See the latest news and media coverage for Colossal. We track all announcements, press releases, and industry mentions in real time, all in one place.
Genetics and biosciences company focused on de-extinction
colossal.comLast updated
In short: Colossal reached a $10.2 billion valuation as it advanced its mission to revive extinct species and launched global conservation efforts.
The Colossal Foundation partners with University of Tasmania to develop a field-ready vaccine and explore genetic resistance using a dunnart colony.
The partnership aims to collect genetic material from over 2100 listed species for conservation and potential de-extinction.
The technology spreads infertility through the population, potentially clearing the parasite in months instead of decades.
Twenty birds bred in Europe are being sent to Vietnam to restore the wild population.
"The red wolf has long been a contentious species. The debate over its preservation got even messier last year, when Colossal said it had cloned...
Colossal Biosciences founder Ben Lamm discusses his company's efforts to bring back extinct species, including the woolly mammoth, dire wolf and saber-toothed tiger. He explains...
Colossal Biosciences announced on April 7, 2025, that it had achieved what it calls the world’s first de-extinction through the birth of three dire wolves...
Endangered Species Act in a project to safeguard roughly 2,300 types of animals and plants deemed th...
Track Colossal and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.